APA (7th ed.) Citation

I, D., R, P., H, G., AM, R., J, P., K, B., . . . T, F. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. Nature communications, 13(1), 7284. https://doi.org/10.1038/s41467-022-34839-9

Chicago Style (17th ed.) Citation

I, Donovan-Banfield, et al. "Characterisation of SARS-CoV-2 Genomic Variation in Response to Molnupiravir Treatment in the AGILE Phase IIa Clinical Trial." Nature Communications 13, no. 1 (2022): 7284. https://doi.org/10.1038/s41467-022-34839-9.

MLA (9th ed.) Citation

I, Donovan-Banfield, et al. "Characterisation of SARS-CoV-2 Genomic Variation in Response to Molnupiravir Treatment in the AGILE Phase IIa Clinical Trial." Nature Communications, vol. 13, no. 1, 2022, p. 7284, https://doi.org/10.1038/s41467-022-34839-9.